At Cytodigm, we believe the future of genetic medicine will be defined not only by scientific discovery, but by how effectively therapies are delivered – and how closely innovators work together to bring them to patients. Partnership is central to our mission.

Cytodigm develops proprietary lipid-based nanoparticle (LNP) delivery platforms engineered for precision, targetability, and efficiency, addressing critical challenges such as tissue distribution, potency, and redosability. Our technologies are designed to support a wide range of modalities, including gene editing tools, in vivo CAR constructs, mRNA and vaccine applications, and next-generation RNA therapeutics.

We work alongside biotech and pharmaceutical partners to integrate our delivery platforms with their therapeutic biology, tailoring solutions to specific research programs and disease targets. Through this approach, we accelerate development, expand therapeutic reach, and reduce risk across cell, gene, and immune-based therapies.

Together, we are creating a new paradigm in genetic medicine — one where transformative in vivo therapies can safely and reliably reach every patient.